Enterin | Gut-Brain Axis | Neurodegenerative DiseaseTime 2022-10-26 18:14:07
Enterin is aiming to become the first company
in the world to develop a novel drug thatrepairs the dysfunctional
in patients with neurodegenerative disease.
In preclinical models of Parkinson’s Disease, ENT-01 displaces
and restores normal signaling between the gut and the brain.
Our lead molecule, ENT-01,
has recently met its primary endpoint
in a Phase 2b study for patients with Parkinson's Disease.
Our clinical data indicates that
repair of the gut-brain axis is able tosignificantly improve
quality of life
by influencing multiple non-motor symptoms that affect patients with Parkinson’s Disease and other neurodegenerative conditions.
Watch an interview with one of Enterin’s founders,Dr. Michael Zasloff, discussing a new hope
autism and other neurodegenerative diseases.
<<< Thank you for your visit >>>